vs
Side-by-side financial comparison of Guardant Health, Inc. (GH) and Strategic Education, Inc. (STRA). Click either name above to swap in a different company.
Strategic Education, Inc. is the larger business by last-quarter revenue ($305.9M vs $281.3M, roughly 1.1× Guardant Health, Inc.). Strategic Education, Inc. runs the higher net margin — 10.7% vs -45.7%, a 56.4% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs 0.8%). Strategic Education, Inc. produced more free cash flow last quarter ($77.3M vs $-54.2M). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs -1.0%).
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
Strategic Education, Inc. (SEI) is an education services holding company and is formerly known as Strayer Education, Inc. The company owns for-profit, online Capella University and Strayer University, as well as non-degree programs schools such as DevMountain, Hackbright Academy, and Sophia Learning.
GH vs STRA — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $281.3M | $305.9M |
| Net Profit | $-128.5M | $32.8M |
| Gross Margin | 64.6% | — |
| Operating Margin | -43.0% | 13.4% |
| Net Margin | -45.7% | 10.7% |
| Revenue YoY | 39.4% | 0.8% |
| Net Profit YoY | -15.8% | 10.3% |
| EPS (diluted) | $-1.01 | $1.48 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $305.9M | ||
| Q4 25 | $281.3M | $323.2M | ||
| Q3 25 | $265.2M | $319.9M | ||
| Q2 25 | $232.1M | $321.5M | ||
| Q1 25 | $203.5M | $303.6M | ||
| Q4 24 | $201.8M | $311.5M | ||
| Q3 24 | $191.5M | $306.0M | ||
| Q2 24 | $177.2M | $312.3M |
| Q1 26 | — | $32.8M | ||
| Q4 25 | $-128.5M | $37.9M | ||
| Q3 25 | $-92.7M | $26.6M | ||
| Q2 25 | $-99.9M | $32.3M | ||
| Q1 25 | $-95.2M | $29.7M | ||
| Q4 24 | $-111.0M | $25.3M | ||
| Q3 24 | $-107.8M | $27.7M | ||
| Q2 24 | $-102.6M | $29.9M |
| Q1 26 | — | — | ||
| Q4 25 | 64.6% | — | ||
| Q3 25 | 64.7% | — | ||
| Q2 25 | 65.0% | — | ||
| Q1 25 | 63.3% | — | ||
| Q4 24 | 61.6% | — | ||
| Q3 24 | 61.1% | — | ||
| Q2 24 | 59.1% | — |
| Q1 26 | — | 13.4% | ||
| Q4 25 | -43.0% | 16.0% | ||
| Q3 25 | -37.3% | 11.6% | ||
| Q2 25 | -45.9% | 14.2% | ||
| Q1 25 | -54.6% | 13.1% | ||
| Q4 24 | -62.4% | 11.6% | ||
| Q3 24 | -61.3% | 11.9% | ||
| Q2 24 | -56.8% | 13.4% |
| Q1 26 | — | 10.7% | ||
| Q4 25 | -45.7% | 11.7% | ||
| Q3 25 | -35.0% | 8.3% | ||
| Q2 25 | -43.0% | 10.1% | ||
| Q1 25 | -46.8% | 9.8% | ||
| Q4 24 | -55.0% | 8.1% | ||
| Q3 24 | -56.3% | 9.1% | ||
| Q2 24 | -57.9% | 9.6% |
| Q1 26 | — | $1.48 | ||
| Q4 25 | $-1.01 | $1.65 | ||
| Q3 25 | $-0.74 | $1.15 | ||
| Q2 25 | $-0.80 | $1.37 | ||
| Q1 25 | $-0.77 | $1.24 | ||
| Q4 24 | $-0.90 | $1.05 | ||
| Q3 24 | $-0.88 | $1.15 | ||
| Q2 24 | $-0.84 | $1.24 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $378.2M | $150.3M |
| Total DebtLower is stronger | $1.5B | — |
| Stockholders' EquityBook value | $-99.3M | $1.6B |
| Total Assets | $2.0B | $2.1B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $150.3M | ||
| Q4 25 | $378.2M | $148.1M | ||
| Q3 25 | $580.0M | $172.6M | ||
| Q2 25 | $629.1M | $164.9M | ||
| Q1 25 | $698.6M | $182.6M | ||
| Q4 24 | $525.5M | $184.0M | ||
| Q3 24 | $585.0M | $222.1M | ||
| Q2 24 | $933.7M | $256.2M |
| Q1 26 | — | — | ||
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $1.6B | ||
| Q4 25 | $-99.3M | $1.6B | ||
| Q3 25 | $-354.5M | $1.7B | ||
| Q2 25 | $-305.5M | $1.7B | ||
| Q1 25 | $-250.8M | $1.6B | ||
| Q4 24 | $-139.6M | $1.7B | ||
| Q3 24 | $-60.1M | $1.7B | ||
| Q2 24 | $-1.6M | $1.7B |
| Q1 26 | — | $2.1B | ||
| Q4 25 | $2.0B | $2.0B | ||
| Q3 25 | $1.3B | $2.1B | ||
| Q2 25 | $1.3B | $2.1B | ||
| Q1 25 | $1.3B | $2.1B | ||
| Q4 24 | $1.5B | $2.0B | ||
| Q3 24 | $1.5B | $2.2B | ||
| Q2 24 | $1.6B | $2.2B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.4M | $87.4M |
| Free Cash FlowOCF − Capex | $-54.2M | $77.3M |
| FCF MarginFCF / Revenue | -19.3% | 25.3% |
| Capex IntensityCapex / Revenue | 9.9% | — |
| Cash ConversionOCF / Net Profit | — | 2.66× |
| TTM Free Cash FlowTrailing 4 quarters | $-233.1M | $173.9M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $87.4M | ||
| Q4 25 | $-26.4M | $39.2M | ||
| Q3 25 | $-35.4M | $60.1M | ||
| Q2 25 | $-60.3M | $31.2M | ||
| Q1 25 | $-62.7M | $67.7M | ||
| Q4 24 | $-64.5M | $15.9M | ||
| Q3 24 | $-51.1M | $51.5M | ||
| Q2 24 | $-94.0M | $24.3M |
| Q1 26 | — | $77.3M | ||
| Q4 25 | $-54.2M | $27.0M | ||
| Q3 25 | $-45.8M | $49.3M | ||
| Q2 25 | $-65.9M | $20.4M | ||
| Q1 25 | $-67.1M | $57.3M | ||
| Q4 24 | $-83.4M | $4.7M | ||
| Q3 24 | $-55.3M | $42.1M | ||
| Q2 24 | $-99.1M | $13.6M |
| Q1 26 | — | 25.3% | ||
| Q4 25 | -19.3% | 8.3% | ||
| Q3 25 | -17.3% | 15.4% | ||
| Q2 25 | -28.4% | 6.3% | ||
| Q1 25 | -33.0% | 18.9% | ||
| Q4 24 | -41.3% | 1.5% | ||
| Q3 24 | -28.9% | 13.8% | ||
| Q2 24 | -55.9% | 4.3% |
| Q1 26 | — | — | ||
| Q4 25 | 9.9% | 3.8% | ||
| Q3 25 | 3.9% | 3.4% | ||
| Q2 25 | 2.4% | 3.4% | ||
| Q1 25 | 2.2% | 3.4% | ||
| Q4 24 | 9.4% | 3.6% | ||
| Q3 24 | 2.2% | 3.1% | ||
| Q2 24 | 2.9% | 3.4% |
| Q1 26 | — | 2.66× | ||
| Q4 25 | — | 1.03× | ||
| Q3 25 | — | 2.26× | ||
| Q2 25 | — | 0.97× | ||
| Q1 25 | — | 2.27× | ||
| Q4 24 | — | 0.63× | ||
| Q3 24 | — | 1.86× | ||
| Q2 24 | — | 0.81× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
STRA
| U.S. Higher Education | $212.6M | 69% |
| Australia/New Zealand | $51.8M | 17% |
| Education Technology Services | $41.5M | 14% |
